Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?

The iShares U.S. Pharmaceuticals ETF (IHE) has outperformed VanEck Pharmaceutical ETF (PPH) over the past year, driven by concentrated exposure to Eli Lilly's GLP-1 drugs, delivering 38.2% returns versus PPH's 26.4%. However, PPH offers global diversification with European pharma giants, a higher dividend yield of 1.9%, and nearly identical expense ratios. IHE suits investors seeking recent momentum, while PPH appeals to those prioritizing international exposure and income.

10/26/2026, 11:40 AM • The Motley Fool

Breakfast News: Science Strikes Back at Cancer

Cancer treatment breakthroughs dominate ESMO 2026 conference with multiple drugs showing significant survival gains. U.S. stocks declined amid AI spending concerns and rising oil prices, with the Fed expected to hold rates steady Wednesday. Several Motley Fool-recommended companies report earnings this week including Alphabet, Amazon, and Mastercard. TransDigm's stock decline reflects valuation compression rather than business deterioration.

10/26/2026, 7:30 AM • The Motley Fool

Microbiotica Presents Phase 1b Clinical Data on MB097 at the European Society for Medical Oncology (ESMO) Congress 2026

Microbiotica announced positive Phase 1b MELODY-1 trial results for MB097, a precision microbiome therapeutic combined with pembrolizumab for advanced melanoma patients resistant to anti-PD-1 therapy. The treatment demonstrated safety, robust bacterial engraftment, and encouraging clinical responses with 14% objective response rate in the vancomycin-preconditioning arm, including deep tumor regressions.

10/26/2026, 3:00 AM • GlobeNewswire

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

The article compares two pharmaceutical giants for 2026 investment. Amgen trades at a lower valuation (forward P/E 19.4x vs JNJ's 24.1x) with strong net margins of 21% and six $1B+ drug franchises, but carries higher debt (6.3x debt-to-equity). Johnson & Johnson offers greater financial stability with lower debt (0.6x), stronger free cash flow ($19.7B), and a diversified portfolio spanning innovative medicines and medical technology, with 28 products generating over $1B annually. The author favors Amgen based on valuation despite JNJ's superior balance sheet strength.

10/24/2026, 12:11 PM • The Motley Fool

Breakfast News: A Conversation With Moderna’s CEO

Moderna's CEO Stéphane Bancel discusses the company's mRNA platform technology and its personalized cancer vaccine intismeran, which showed promising phase 3 trial results for melanoma when combined with Merck's Keytruda. The CEO emphasizes Moderna's platform approach, high clinical trial success rate (85% vs. 10% industry average), patent strategy, and long-term investment focus over quarterly earnings. He also revealed buying company stock at $29 during the COVID sales decline, demonstrating confidence in the company's future pipeline including rare genetic diseases and autoimmune treatments.

10/24/2026, 7:30 AM • The Motley Fool

Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?

Moderna stock dropped 17% after leaked data from its phase 3 cancer vaccine trial, despite the data showing positive results (42% reduction in recurrence/death risk for melanoma patients). The stock has surged over 500% this year and trades at $200, well above Wall Street's $135 price target. While the dip may present a buying opportunity for long-term investors, the stock remains volatile and sensitive to clinical trial announcements.

10/23/2026, 9:55 AM • The Motley Fool

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Moderna's stock fell 18% after reports of a data leak regarding its personalized melanoma vaccine showed a 42% reduction in recurrence or death risk when paired with Merck's Keytruda—lower than Phase II results of 49%. The full Phase 3 results were scheduled for release on October 24, and the leaked figures fell short of market expectations despite the company's 600% gain in 2026.

10/22/2026, 4:45 PM • The Motley Fool

Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR. North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

10/21/2026, 1:00 PM • GlobeNewswire

Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026

Moderna has surged over 600% in 2026, driven by breakthrough Phase 3 trial results for its personalized cancer vaccine (intismeran autogene) combined with Merck's Keytruda, plus FDA approval for its flu vaccine mFLUSIVA. However, despite strong innovation, the stock appears overvalued at a $90 billion market cap with a 45% downside according to Wall Street analysts. The company would need to generate unrealistic revenue levels to justify current valuations, leaving little room for error.

10/21/2026, 10:00 AM • The Motley Fool

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice

Moderna is transitioning from a COVID-19 vaccine company to an oncology-focused biotech firm. The company announced positive phase 3 results for its personalized cancer vaccine (intismeran autogene) paired with Merck's Keytruda for melanoma treatment. With the global oncology market projected to grow from $253 billion to over $700 billion by 2034, Moderna's stock has surged over 600% this year, though it now trades 61% above Wall Street's average price target of $123.

10/21/2026, 4:02 AM • The Motley Fool

Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million

Surrozen, Inc. (NASDAQ: SRZN) announced the closing of its second tranche of a private placement, raising approximately $95.1 million in gross proceeds. The closing was triggered by FDA clearance of the IND application for SZN-8141 on October 2, 2026. The company now has cash runway into 2029 to advance its ophthalmology pipeline, including the DUET Phase 1b/2a study of SZN-8141 for diabetic macular edema and initial clinical development of SZN-8143. First patient dosing in the DUET study is expected in Q4 2026, with initial data anticipated in H2 2027.

10/20/2026, 4:59 PM • GlobeNewswire

Catholic Medical Mission Board and Church of the Brethren to mark partnership with ribbon-cutting

Catholic Medical Mission Board (CMMB) opened its new Distribution Center at the Brethren Service Center in New Windsor, Maryland on October 22, 2026. The relocation expands CMMB's operational capacity for its Access to Medicines Program, which distributed $243.5 million worth of medicines and medical supplies to 64 partners across 28 countries in 2025. The partnership strengthens both organizations' humanitarian efforts.

10/20/2026, 2:55 PM • GlobeNewswire

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

Moderna has been added to the Nasdaq-100 index following a 700% stock surge this year, driven by FDA approvals of updated COVID-19 and flu vaccines, as well as promising phase 3 trial results for its cancer vaccine candidate. The inclusion will increase institutional ownership and potentially raise the stock price, though investors should focus on the company's future potential with its cancer vaccine pipeline.

10/18/2026, 8:45 AM • The Motley Fool

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation.

10/16/2026, 8:50 PM • The Motley Fool

Novo Nordisk and Eli Lilly Just Got Some Fantastic News

A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035.

10/16/2026, 11:32 AM • The Motley Fool